FDA label f68a2ea6-e62f-4a7b-8acb-64ebb0b89e37

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
429e9731-cc5d-4089-bf4a-81ec22824c9e
SPL ID
f68a2ea6-e62f-4a7b-8acb-64ebb0b89e37
Version
2
Effective date
2016-06-16
Source export date
2026-10-12
Source partition
13
Source file
https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/b8dac220ac9fc8ffb4d86c6e00ece30169fc4575ca0cc92e5c9ce1a524fb0249/drug-label-0013-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 03:04:38

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (See and ). WARNINGS PRECAUTIONS • Indomethacin Extended-release Capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (See and ). CONTRAINDICATIONS WARNINGS Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See ). WARNINGS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS:

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 3 · 12 matching rows.

adverse reactions table

<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">tinnitus </td> <td align="left" valign="top">ocular-corneal deposits and retinal disturbances, including those of macula, have been reported in some patients on prolonged therapy with indomethacin </td> <td align="left" valign="top"> <paragraph>blurred vision</paragraph> <paragraph>diplopia</paragraph> <paragraph>hearing disturbances, deafness </paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>hypertension</paragraph> <paragraph>hypotension</paragraph> <paragraph>tachycardia</paragraph> <paragraph>chest pain </paragraph> </td> <td align="left" valign="top"> <paragraph>congestive heart failure</paragraph> <paragraph>arrhythmia; palpitations </paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>edema</paragraph> <paragraph>weight gain</paragraph> <paragraph>fluid retention</paragraph> <paragraph>flushing or sweating </paragraph> </td> <td align="left" valign="top"> <paragraph>hyperglycemia</paragraph> <paragraph>glycosuria hyperkalemia </paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>pruritus</paragraph> <paragraph>rash; urticaria</paragraph> <paragraph>petechiae or ecchymosis </paragraph> </td> <td align="left" valign="top"> <paragraph>exfoliative dermatitis</paragraph> <paragraph>erythema nodosum</paragraph> <paragraph>loss of hair</paragraph> <paragraph>Stevens-Johnson syndrome</paragraph> <paragraph>erythema multiforme</paragraph> <paragraph>toxic epidermal necrolysis </paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.